© 1995 American Heart Association, Inc.
Articles |
Inhibition of Hypercholesterolemia-Induced Atherosclerosis in the Nonhuman Primate by Probucol
II. Cellular Composition and Proliferation
From the Department of Medicine (M.Y.C., A.C.) and the Department of Pathology (E.W.R., R.R.), University of Washington, Seattle, and the Department of Pathology (M.S.), Shiga University of Medical Science, Otsu, Japan.
Correspondence to Russell Ross, PhD, Department of Pathology, University of Washington School of Medicine, Box 357470, Seattle, WA 98195-7470. E-mail rross@u.washington.edu.
Abstract In nonhuman primates (Macaca nemestrina) treated with the antioxidant probucol during diet-induced hypercholesterolemia, intimal lesion area in the thoracic aorta was decreased, with increased resistance of plasma LDL to oxidation. The cellular and molecular changes associated with the decrease in lesion size in the probucol-treated hypercholesterolemic animals are quantitatively evaluated in this study. Lesions from the probucol-treated animals appear less mature and have altered lipid distribution. Abundant lipid-laden smooth muscle cells are found in the intima and media of the probucol-treated animals, with fewer medial lipid-laden macrophages, compared with lesions at similar sites in the control hypercholesterolemic animals. In both the control and probucol-treated animals, macrophages are the predominant cells in most lesions, but the ratio of macrophages to smooth muscle cells is decreased in the lower thoracic and upper abdominal aortic sites in the probucol-treated animals. Lesions at all aortic sites in the probucol-treated animals have a 35% to 80% reduction in the percentage of cells in cell cycle traverse, as indicated by immunostaining for proliferating cell nuclear antigen (% PCNA-positive). In both groups, macrophages and smooth muscle cells are PCNA-positive, but the majority (>60%) are macrophages. No difference in % PCNA-positive cells is seen in the iliac arteries, where the most advanced lesions were present at the time probucol administration was initiated. Limited Northern analysis of growth-regulatory molecules possibly involved in the cellular changes associated with lesions shows a 30% to 50% decrease in mRNA levels of platelet-derived growth factor (PDGF) B-chain, PDGF ß-receptor, colony-stimulating factor type 1, and monocyte chemotactic protein 1. Thus, a potential role for an antioxidant such as probucol in the treatment of atherosclerosis may be to alter the early inflammatory fibroproliferative processes of the disease. Whether these effects are directly related to the antioxidant properties or some other activity of probucol is not yet known.
Key Words: LDL • antioxidant • atherosclerotic lesions • cellular composition • proliferating cell nuclear antigen
This article has been cited by other articles:
 |
|
 |
|
  B. J. Wu, N. Di Girolamo, K. Beck, C. G. Hanratty, K. Choy, J. Y. Hou, M. R. Ward, and R. Stocker Probucol [4,4'-[(1-Methylethylidene)bis(thio)]bis-[2,6-bis(1,1-dimethylethyl)phenol]] Inhibits Compensatory Remodeling and Promotes Lumen Loss Associated with Atherosclerosis in Apolipoprotein E-Deficient Mice J. Pharmacol. Exp. Ther., May 1, 2007; 321(2): 477 - 484. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Choy, K. Beck, F. Y. Png, B. J. Wu, S. B. Leichtweis, S. R. Thomas, J. Y. Hou, K. D. Croft, T. A. Mori, and R. Stocker Processes Involved in the Site-Specific Effect of Probucol on Atherosclerosis in Apolipoprotein E Gene Knockout Mice Arterioscler. Thromb. Vasc. Biol., August 1, 2005; 25(8): 1684 - 1690. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Navab, G.M. Anantharamaiah, S. Hama, G. Hough, S. T. Reddy, J. S. Frank, D. W. Garber, S. Handattu, and A. M. Fogelman D-4F and Statins Synergize to Render HDL Antiinflammatory in Mice and Monkeys and Cause Lesion Regression in Old Apolipoprotein E-Null Mice Arterioscler. Thromb. Vasc. Biol., July 1, 2005; 25(7): 1426 - 1432. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. K. Lau, S. B. Leichtweis, P. Hume, R. Mashima, J. Y. Hou, X. Chaufour, B. Wilkinson, N. H. Hunt, D. S. Celermajer, and R. Stocker Probucol Promotes Functional Reendothelialization in Balloon-Injured Rabbit Aortas Circulation, April 22, 2003; 107(15): 2031 - 2036. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Sawayama, C. Shimizu, N. Maeda, M. Tatsukawa, N. Kinukawa, S. Koyanagi, S. Kashiwagi, and J. Hayashi Effects of probucol and pravastatin on common carotid atherosclerosis in patients with asymptomatic hypercholesterolemia: Fukuoka atherosclerosis trial (FAST) J. Am. Coll. Cardiol., February 20, 2002; 39(4): 610 - 616. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Aoki, T. Nata, R. Morishita, H. Matsushita, H. Nakagami, K. Yamamoto, K. Yamazaki, M. Nakabayashi, T. Ogihara, and Y. Kaneda Endothelial Apoptosis Induced by Oxidative Stress Through Activation of NF-{kappa}B: Antiapoptotic Effect of Antioxidant Agents on Endothelial Cells Hypertension, July 1, 2001; 38(1): 48 - 55. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Y. Chang, S. Potter-Perigo, T. N. Wight, and A. Chait Oxidized LDL bind to nonproteoglycan components of smooth muscle extracellular matrices J. Lipid Res., May 1, 2001; 42(5): 824 - 833. [Abstract] [Full Text]
|
|
|
|
|
|
F. Rinninger, N. Wang, R. Ramakrishnan, X. C. Jiang, and A. R. Tall Probucol Enhances Selective Uptake of HDL-Associated Cholesteryl Esters In Vitro by a Scavenger Receptor B-I–Dependent Mechanism Arterioscler. Thromb. Vasc. Biol., May 1, 1999; 19(5): 1325 - 1332. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Shindo, T. Ishibashi, K. Yokoyama, K. Nakazato, T. Ohwada, M. Shiomi, and Y. Maruyama Granulocyte-Macrophage Colony–Stimulating Factor Prevents the Progression of Atherosclerosis via Changes in the Cellular and Extracellular Composition of Atherosclerotic Lesions in Watanabe Heritable Hyperlipidemic Rabbits Circulation, April 27, 1999; 99(16): 2150 - 2156. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Ross Atherosclerosis -- An Inflammatory Disease N. Engl. J. Med., January 14, 1999; 340(2): 115 - 126. [Full Text] [PDF]
|
|
|
|
|
|
R. S. Crawford, E. A. Kirk, M. E. Rosenfeld, R. C. LeBoeuf, and A. Chait Dietary Antioxidants Inhibit Development of Fatty Streak Lesions in the LDL Receptor–Deficient Mouse Arterioscler. Thromb. Vasc. Biol., September 1, 1998; 18(9): 1506 - 1513. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. A. Bird, R. K. Tangirala, J. Fruebis, D. Steinberg, J. L. Witztum, and W. Palinski Effect of probucol on LDL oxidation and atherosclerosis in LDL receptor-deficient mice J. Lipid Res., May 1, 1998; 39(5): 1079 - 1090. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Fruebis, V. Gonzalez, M. Silvestre, and W. Palinski Effect of Probucol Treatment on Gene Expression of VCAM-1, MCP-1, and M-CSF in the Aortic Wall of LDL Receptor–Deficient Rabbits During Early Atherogenesis Arterioscler. Thromb. Vasc. Biol., July 1, 1997; 17(7): 1289 - 1302. [Abstract] [Full Text]
|
|
|
|
 |
|
 S. Rangaswamy, M. S. Penn, G. M. Saidel, and G. M. Chisolm Exogenous Oxidized Low-Density Lipoprotein Injures and Alters the Barrier Function of Endothelium in Rats In Vivo Circ. Res., January 1, 1997; 80(1): 37 - 44. [Abstract] [Full Text]
|
|
|
|
|
|
X. Wang, C. Louden, E. H. Ohlstein, J. M. Stadel, J.-L. Gu, and T.-L. Yue Osteopontin Expression in Platelet-Derived Growth Factor–Stimulated Vascular Smooth Muscle Cells and Carotid Artery After Balloon Angioplasty Arterioscler. Thromb. Vasc. Biol., November 1, 1996; 16(11): 1365 - 1372. [Abstract] [Full Text]
|
|